NESS ZIONA, Israel, August 10, 2016 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it has been invited to participate in the 'Eighth WHO meeting on the development of influenza vaccines that induce broadly protective and long-lasting immune responses'. The meeting will be held in Chicago, IL on August 23 and 24, 2016.
The Global Vaccine Action Plan (GVAP) aims for at least one licensed universal influenza vaccine by 2020. The World Health Organization (WHO) Initiative for Vaccine Research monitors progress toward the achievement of GVAP goals through consultations of experts in the field. Having completed 5 clinical trials, and with two ongoing Phase 2 trials sponsored by the EU's UNISEC and the US NIH/DMID, BiondVax's M-001 is recognized as a leading universal flu vaccine candidate. M-001's clinical trial results have shown safety and immunogenicity in both young and elderly adults against a broad range of seasonal and pandemic flu strains.
Joshua Phillipson, BiondVax's Head of Business Development, commented, "The meeting's participants, leading public health and influenza experts, recognize the urgent need for a next generation flu vaccine that broadly protects against future seasonal and pandemic flu strains. Current solutions fall short. BiondVax's vaccine candidate is unique in that it's in advanced human clinical trials, and is designed to be a 'one size fits all' flu vaccine. It can be used year round, and stockpiled for future pandemics. I'm looking forward to meeting with our colleagues and contributing to the discussion at the upcoming WHO meeting."
BiondVax will be participating along with representatives from WHO, NIH, BARDA, and other leading industry experts.
For more information about the WHO meeting, please see http://who.int/immunization/research/meetings_workshops/8th_influenza_vaccine_chicago2016/en/.
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.
For further information, please contact:
Joshua E Phillipson Business Development +972-8-930-2529 x5105 firstname.lastname@example.org
Kenny Green Investor Relations +1-646-201-9246 email@example.com
SOURCE BiondVax Pharmaceuticals Ltd.